Actively Recruiting
Impact of Early PCSK9 Inhibitor on Heart After Acute Myocardium Infarction
Led by Shanghai Tong Ren Hospital · Updated on 2025-05-21
20
Participants Needed
2
Research Sites
233 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a prospect, multi-center, random study to investigate whether early offering PCSK9 inhibitor to acute myocardium infarction(AMI) can alleviate ventricular remodeling after primary percutaneous intervention(PPCI). Totally,twenty acute myocardium infarction subjects will be enrolled in this study after consent information. After randomization, the control group will receive standard therapy for AMI including PPCI. The experiment group will receive first PCSK9 inhibitor before PPCI, then twice a month until 3 months later. Six month after AMI, Myocardial salvage index will be used to evaluate ventricular remodeling. TnI peaking time and LDL control rates also will be recorded and compared.
CONDITIONS
Official Title
Impact of Early PCSK9 Inhibitor on Heart After Acute Myocardium Infarction
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 to less than 80 years
- Successful percutaneous coronary intervention with drug-eluting stent for acute myocardial infarction
- Left anterior descending artery is the only affected vessel
- Able to understand study requirements and provide informed consent before procedure
You will not qualify if you...
- Female of childbearing potential unless recent pregnancy test is negative and no plan to become pregnant during study
- Known allergy or contraindication to study medications
- Planning to have revascularization within six months
- Previous revascularization procedure
- Life expectancy less than one year
- Active cancer
- Severe liver dysfunction (ALT >5 times upper limit of normal) or severe kidney dysfunction (eGFR <15 ml/min/1.73m2)
- Other conditions judged unsuitable by investigators
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Tongren Hospital, Shanghai
Shanghai, Shanghai Municipality, China
Actively Recruiting
2
Shanghai tenth people's hospital
Shanghai, China
Actively Recruiting
Research Team
L
Lei Hou, Doctor
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here